Loading...
Market
Will SLS-002 demonstrate significant efficacy in the Phase II M-PACT trial for PTSD by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Trial results published by USAMMDA or Seelos Therapeutics
Story
Seelos Therapeutics ($SEEL) Signs Agreement with USAMMDA to Evaluate SLS-002 for PTSD, Stock Surges 115.8%
Sep 24, 2024, 12:38 PM
Seelos Therapeutics ($SEEL) has announced the signing of a Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate its intranasal ketamine, SLS-002, for the treatment of PTSD. This agreement includes the inclusion of SLS-002 in the U.S. Department of Defense’s M-PACT trial, which will begin dosing in the fourth quarter of 2024. The Phase II trial will assess the safety, efficacy, and tolerability of SLS-002 in active-duty service members and veterans. Following this announcement, Seelos Therapeutics' stock surged by 115.8% in pre-market trading.
View original story
Similar markets
Yes • 50%
No • 50%
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Yes • 50%
No • 50%